RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC
Beyfortus, a new shot for RSV, was 90% effective at preventing hospitalizations in children, new data shows.
A new monoclonal antibody product to protect against respiratory syncytial virus was 90% effective at preventing little children from being hospitalized with RSV, according to new data from the first season it was in use.
The data, published Thursday in Morbidity and Mortality Weekly Report, a Centers for Disease Control and Prevention publication, looked at how well Beyfortus worked in the children whose parents managed to secure a scarce dose of the drug. These are the first real-world data showing how effective the product was in the United States.
What's Your Reaction?
